Welcome to our dedicated page for DANAHER /DE/ SEC filings (Ticker: DHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on DANAHER /DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into DANAHER /DE/'s regulatory disclosures and financial reporting.
Danaher Corporation furnished a current report to share its latest financial performance. On January 28, 2026, the company issued a press release detailing results for the year ended December 31, 2025, including fourth quarter performance, and attached this release as Exhibit 99.1.
The information was furnished under Item 2.02 and is expressly stated as not being deemed “filed” for liability purposes or automatically incorporated into other securities law filings, unless specifically referenced in a future document.
Danaher Corporation is providing an early look at its financial performance, sharing estimated results for the fourth quarter of 2025 and for full-year 2025. On January 12, 2026, the company issued a press release and presentation slides in connection with a public webcast at the J.P. Morgan Healthcare Conference on January 13, 2026. These materials, furnished under a current report, outline management’s view of recent performance and are incorporated by reference as exhibits, but are expressly designated as furnished rather than filed under securities law.
Danaher Corporation director and executive Mitchell P. Rales increased his deferred stock-based holdings through a plan contribution. On 12/30/2025, he acquired 1,543.981 derivative interests tied to Danaher common stock through the Danaher Deferred Compensation Plan’s Danaher Stock Fund.
The contribution is recorded as notional shares that track Danaher common stock on a one-for-one basis, with an exercise price of $0.00 and a reference price of $230.67 per share. Following this transaction, Rales held 7,969.204 derivative securities linked to Danaher stock in this plan. All deferrals in this stock fund are described as immediately vested, meaning the economic rights tied to these notional shares are fully earned when contributed.
Danaher Corp. (DHR) director and officer Mitchell P. Rales reported selling common stock in the company. On November 25, 2025, a family trust for which he serves as trustee sold 35,899 shares at a weighted average price of $230.27 and 4,726 shares at a weighted average price of $231.19.
After these transactions, the Mitchell P. Rales Family Trust held 850,000 Danaher shares. Rales also has additional beneficial holdings, including 553,228 shares held directly, shares in a 401(k) plan, shares in custodial accounts for his daughter (for which he disclaims beneficial ownership), and 25,671,000 shares held through single-member LLCs owned by a revocable trust of which he is sole trustee and beneficiary.
Danaher (DHR) insider Mitchell P. Rales filed a Rule 144 notice covering the planned sale of 40,625 shares of common stock through broker Monness, Crespi, Hardt & Co., Inc. on or about 11/25/2025, with an aggregate market value of $9,221,063. The filing notes that 706,349,563 shares of Danaher common stock were outstanding for context and that the shares are listed on the NYSE.
The securities to be sold were originally acquired on 06/11/2021 as part of a distribution from closely held Capital Yield Corporation, totaling 1,900,000 shares, with no cash payment due to the liquidation of that corporation. Over the past three months, Rales has already sold 600,000 shares of Danaher common stock on 10/31/2025 for gross proceeds of $129,635,820 and a further 437,000 shares on 11/12/2025 for gross proceeds of $95,566,167.
By signing the notice, the seller represents that he is not aware of any undisclosed material adverse information about Danaher’s current or prospective operations.
Danaher Corporation has a notice for the potential sale of 146,957 shares of common stock through broker Monness, Crespi, Hardt & Co., Inc. on the NYSE. The shares have an indicated aggregate market value of $33,356,300 based on the information provided, with 706,349,563 shares outstanding of this class. The approximate sale date listed is 11/25/2025.
The shares to be sold were acquired as common stock via a gift from affiliate Mitchell P. Rales on 06/11/2021, with the donor’s original acquisition date of 12/16/1983. The consideration is described as "None - gift to foundation", indicating the securities were transferred to a foundation rather than purchased for cash.
Danaher Corporation (DHR) director and officer Mitchell P. Rales reported an insider transaction involving Danaher common stock. On 11/25/2025, a family trust for which he serves as trustee transferred 22,029 shares of common stock as a gift at a reported price of $0. Following this transaction, that family trust held 890,625 shares indirectly.
In addition, Rales is shown as holding 553,228 shares directly, 667 shares through a 401(k) plan, and 3,256 shares in custodial accounts for his daughter, for which he disclaims beneficial ownership. A further 25,671,000 shares are held indirectly through single-member LLCs owned by a revocable trust of which he is sole trustee and beneficiary.
Danaher Corporation director Form 4 filing reports an option exercise and share sale. On 11/18/2025, a director exercised a stock option for 3,298 shares of Danaher common stock at an exercise price of $71.88 per share. That same day, the director sold 3,298 shares of common stock at a price of $226.50 per share. After these transactions, the director beneficially owned 20,761.994 shares of Danaher common stock held directly.
Danaher Corporation (DHR) reported an insider equity transaction by senior executive R. Bradley Gray, who serves as SVP Strategic Development. On 11/15/2025, Gray disposed of 1,402 shares of Danaher common stock at a price of $221.21 per share, as shown by transaction code "F" on the Form 4. After this transaction, Gray beneficially owned 11,614 shares of Danaher common stock in direct ownership. The filing indicates it was submitted by one reporting person and lists no derivative securities transactions.
Danaher Corporation (DHR) reported new equity awards to its Senior Vice President and General Counsel, Jonathan Leiken. On November 15, 2025, he received 10,172 restricted stock units (RSUs) that are payable solely in common stock and were recorded at a price of $0 per share. One third of these RSUs vest on each of the first, second, and third anniversaries of the grant date. On the same date, he was also granted an employee stock option to purchase 26,767 shares of common stock at an exercise price of $221.21 per share, with one third of the options becoming exercisable on each of the first three anniversaries of November 15, 2025.